NCT07441967
Not yet recruiting
Phase 2
A Prospective, Single-arm, Single-center, Open-label Clinical Study on the Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation for Elderly Patients With Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China0 sites44 target enrollmentStarted: February 20, 2026Last updated:
Overview
- Phase
- Phase 2
- Status
- Not yet recruiting
- Enrollment
- 44
- Primary Endpoint
- 180-day non-recurrence mortality rate
Overview
Brief Summary
This trial is a prospective, single-arm, single-center clinical study. A total of 44 elderly (aged 60 to 69 years) patients with hematological malignancies who need to receive a single-unit unrelated umbilical cord blood transplantation (UCBT) are planned to be enrolled. After screening and enrollment, patients are scheduled to receive the following drug treatment regimen: Thiotepa 5 mg/kg every 12 hours on day -8; Granulocyte Colony-Stimulating Factor(G-CSF) 5 ug/kg/day from day -8 to -5; Cytarabine 1.5 g/m2 from day -7 to -5; Fludarabine 30 mg/m2/day from day -7 to -4; Busulfan 0.8 mg/kg every 6 hours from day -4 to -2. Umbilical cord blood hematopoietic stem cells are reinfused on day 0. Routine monitoring of blood routine is conducted, and platelets and red blood cells are transfused when necessary.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 60 Years to 69 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Aged between 60 and 69 years old (inclusive), gender not restricted.
- •Patients with hematological malignancies who plan to receive a single unrelated umbilical cord blood transplantation treatment
- •The liver and kidney functions, as well as the heart and lung functions, must meet the following requirements:
- •Serum creatinine ≤ 1.5 × ULN
- •Cardiac function: Ejection fraction \> 50%
- •Baseline oxygen saturation \> 92%
- •Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN
- •Pulmonary function: DLCO (hemoglobin-corrected) \> 65% and FEV1 \> 65%
- •ECOG PS≤2
- •Expected survival period ≥ 6 months
Exclusion Criteria
- •For those who are allergic to the drugs and their related metabolites
- •Any unstable systemic diseases: including but not limited to stable angina pectoris, cerebrovascular accident or transient cerebral ischemia (within 3 months before screening), myocardial infarction (within 3 months before screening), congestive heart failure (NYHA classification ≥ 3), severe arrhythmias requiring drug treatment, liver, kidney or metabolic diseases; patients with pulmonary hypertension; or diseases that, in the judgment of the investigator, pose a serious threat to the safety of the patient or affect the patient's ability to complete the study.
- •Active and uncontrolled infection: Hemodynamic instability related to the infection, or new symptoms or signs of infection appear, or new infection lesions are found on imaging, or persistent fever without symptoms or signs that cannot rule out the presence of an infection.
- •The patient is currently involved in a clinical intervention study
- •The patient is unable to understand the nature of the study or has not given informed consent
- •Other circumstances where the researcher deems the patient unsuitable for inclusion in this study
Arms & Interventions
Thiotepa + fludarabine + G-CSF + cytarabine + busulfan
Experimental
Intervention: Thiotepa (Drug)
Thiotepa + fludarabine + G-CSF + cytarabine + busulfan
Experimental
Intervention: Fludarabine (Drug)
Thiotepa + fludarabine + G-CSF + cytarabine + busulfan
Experimental
Intervention: G-CSF (Drug)
Thiotepa + fludarabine + G-CSF + cytarabine + busulfan
Experimental
Intervention: cytarabine (Drug)
Thiotepa + fludarabine + G-CSF + cytarabine + busulfan
Experimental
Intervention: busulfan (Drug)
Outcomes
Primary Outcomes
180-day non-recurrence mortality rate
Time Frame: 180-day
Secondary Outcomes
- One-year progression-free survival rate after transplantation(One-year after transplantation)
- The cumulative implantation rate of neutrophils(One month after the transplantation)
- The cumulative implantation rate of platelets(One month after the transplantation)
- The cumulative implantation time of platelets(One month after the transplantation)
- The cumulative implantation time of neutrophils(One month after the transplantation)
- The cumulative incidence and severity of acute and chronic graft-versus-host disease (GVHD)(Two years after the transplantation)
- The cumulative recurrence rate one year after transplantation(one year after transplantation)
- One-year overall survival rate after transplantation(One year after transplantation)
Investigators
Similar Trials
Not yet recruiting
Not Applicable
A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy ProgressionNCT07289048Union Hospital, Tongji Medical College, Huazhong University of Science and Technology35
Not yet recruiting
Phase 2
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICCNCT07432568Tianjin Medical University Cancer Institute and Hospital30
Not yet recruiting
Phase 2
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid TumorsNCT07327411Second Affiliated Hospital of Soochow University40
Not yet recruiting
Phase 2
A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical CancerNCT07348861Zheng Min25
Recruiting
Phase 2
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ AdenocarcinomaNCT07277439The First Affiliated Hospital with Nanjing Medical University48